Focusing on the essential information you need to know for the clinical practice of oncology, this practical volume in the Lippincott Manual series provides concise, high-yield content that reflects today's fast-changing advances in the field. In one convenient, portable resource, you'll find complete coverage of cancer management, all at your fingertips for quick review and reference. The Washington Manual (R) of Oncology, 4th Edition, by Drs. Daniel Morgensztern, Armin Ghobadi, and Ramaswamy Govindan, is an ideal reference for oncologists, residents, fellows, medical students, nurse practitioners, and physician assistants. , The latest, most reliable cancer management recommendations in the famous fast-access Washington Manual (R) outline format that includes easy-to-follow guidelines, tables, graphs, and algorithms. Thoroughly revised from cover to cover, including new content on gene and cellular immunotherapy for cancer, management of antineoplastic-induced nausea and vomiting as well as new sections on neuroendocrine carcinoma and myelodysplastic syndromes. Concise, clearly written sections on the principles of oncology, site-specific cancers, and therapy and support. Key information on chemotherapeutic agents and regimens in the appendices. The Washington Manual (R) is a registered mark belonging to Washington University in St. Louis to which international legal protection applies. The mark is used in this publication by WoltersKluwer Health under license from Washington University. , Enrich Your eBook Reading Experience Read directly on your preferred device(s), such as computer, tablet, or smartphone. Easily convert to audiobook, powering your content with natural language text-to-speech. ,

This issue of Hematology/Oncology Clinics will focus on lung cancer; specifically, Genomics in lung cancer; Neoadjuvant and adjuvant therapy for NSCLC; Treatment of locally advanced NSCLC; First line systemic therapy for NSCLC; Second line chemotherapy and beyond for NSCLC; Treatment of EGFR mutant tumors; Treatment of ALK positive tumors; New targets in NSCLC; Immunotherapy; Advances in Small cell lung cancer; and many more!